Progyny (PGNY) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Market Leadership and Growth

• Leading position in a large, growing market with over 530 clients and 6.7 million covered lives, expanding from two industries to more than 45.

• Client retention exceeds 99% since inception, with high NPS scores and a mission-driven approach.

• Expansion into adjacent women's health areas, including menopause, postpartum, and mental health, with strong initial uptake and 30% of clients adding new services in 2025.

• Partnerships with major health plans, PBMs, and clinical partners, including Cigna and regional payers, extend market reach and validate the business model.

• Addressable market expanded from 69 million lives in 2019 to 106 million in 2025, with TAM expansion targeting middle market, global, and fully insured employers.

Differentiated Solution and Clinical Outcomes

• Data-driven, transparent reporting on clinical outcomes and member journeys, with significant reductions in costly IVF retrievals and higher live birth rates.

• Flexible, comprehensive plan design avoids one-size-fits-all, supporting equitable and cost-effective care.

• Over half of members resolve needs through non-medical interventions, and those requiring care achieve better results with fewer treatments.

• Model delivers 30% cost savings compared to alternatives and national averages, with improved recruitment, retention, and productivity for clients.

• Unique alignment of provider network, benefit management, and personalized coaching, difficult for competitors to replicate.

Financial and Operational Performance

• Profitable with nearly $500 million in operating cash flow from 2020 to 2024; $300 million in share buybacks completed in 2024.

• Revenue growth driven by new client acquisition, high retention, upsells, new product adoption, and TAM expansion.

• Maintains a flexible operating model, leveraging scale to expand margins and generate meaningful cash flow.

• Capital priorities include share repurchases, investments in new products, go-to-market resources, and selective M&A.

• Non-GAAP measures such as Adjusted EBITDA are used for internal planning and performance assessment.